DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. 03N–0170]

Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Commitment Studies; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA) is required, under the Food and Drug Administration Modernization Act of 1997 (Modernization Act), to report annually in the Federal Register on the status of postmarketing study commitments made by sponsors of approved drug and biological products. This is the agency’s first report on the status of the study commitments that sponsors have agreed to conduct and for which an annual status report on the study has been received by FDA.


SUPPLEMENTARY INFORMATION:

I. Background

Section 130(a) of the Modernization Act (Public Law 105–115) amended the Federal Food, Drug, and Cosmetic Act (the act) by adding a new provision (section 506B of the act (21 U.S.C. 356b)) requiring reports of postmarketing studies for human drugs and biological products. Section 506B provides FDA with additional authority to monitor the progress of a postmarketing study commitment that an applicant has been required or has agreed to conduct by requiring the applicant to submit a report annually providing information on the status of the postmarketing study commitment. This report must also include reasons, if any, for failure to complete the commitment.

On December 1, 1999 (64 FR 67207), FDA published a proposed rule providing a framework for the content and format of the annual progress report. The proposed rule also clarified the scope of the reporting requirement and timing for submission of the annual progress reports. The final rule, published on October 30, 2000 (65 FR 64607), modified annual report requirements for new drug applications (NDAs) and abbreviated new drug applications (ANDAs) by establishing § 314.81(b)(2)(vii) (21 CFR 314.81(b)(2)(vii)). The rule also created a new annual reporting requirement for biologics license applications (BLAs) by establishing § 601.70 (21 CFR 601.70).

These regulations became effective on April 26, 2001. The regulations apply only to human drugs, including biological drugs. They do not apply to animal drugs or to licensed biological products that also meet the definition of a medical device.

Sections 314.81(b)(2)(vii) and 601.70 apply to postmarketing commitments made on or before enactment of the Modernization Act (November 21, 1997) as well as those made after that date. Sections 314.81(b)(2)(vii) and 601.70 require applicants of approved drugs and biological products to submit annually a report on the status of each clinical efficacy, clinical pharmacology, and nonclinical toxicology study that is required by FDA (e.g., accelerated approval clinical benefit studies) or that they have committed to conduct either at the time of approval or after approval of their NDA, ANDA, BLA or supplement. The status of other types of postmarketing commitments (e.g., those concerning chemistry, manufacturing, production controls, and studies conducted on an applicant’s own initiative) are not required to be reported under §§ 314.81(b)(2)(vii) and 601.70 and are not addressed in this report. It should be noted, however, that applicants are required to report to FDA on these commitments made for NDAs and ANDAs under § 314.81(b)(2)(vii).

According to the regulations, once a postmarketing study commitment has been made, an applicant must report on the progress of the commitment on the anniversary of the product’s approval until the postmarketing study commitment is completed or terminated and FDA determines that the postmarketing study commitment has been fulfilled or that the postmarketing study commitment is either no longer feasible or would no longer provide useful information. The annual progress report must include a description of the postmarketing study commitment, a schedule for completing the study commitment, and a characterization of the current status of the study commitment. The report must also provide an explanation of the postmarketing study commitment’s status by describing briefly the postmarketing study commitment’s progress.

A postmarketing study commitment schedule is expected to include the actual or projected dates for: (1) Submission of the study protocol to FDA, (2) completion of patient accrual or initiation of an animal study, (3) completion of the study, and (4) submission of the final study report to FDA. The postmarketing study commitment status must be described in the annual report according to the following definitions:

• Pending: The study has not been initiated, but does not meet the criterion for delayed;
• Ongoing: The study is proceeding according to or ahead of the original schedule;
• Delayed: The study is behind the original schedule;
• Terminated: The study was ended before completion, but a final study report has not been submitted to FDA; or
• Submitted: The study has been completed or terminated, and a final study report has been submitted to FDA.

Databases containing information on postmarketing study commitments are maintained at the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). Information in this report covers any postmarketing study commitment that was made, in writing, at the time of approval or after approval of an application or a supplement to an application, including those required (e.g., to demonstrate clinical benefit of a product following accelerated approval) and those agreed to with the applicant. Information summarized in this report includes: (1) The number of applicants with open (uncompleted) postmarketing commitments, (2) the number of open postmarketing commitments, (3) the status of open postmarketing commitments as reported in § 314.81(b)(2)(vii) or § 601.70 annual

clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0509. The approval expires on October 31, 2003. A copy of the supporting statement for this information collection is available on the Internet at http://www.fda.gov/ohrms/dockets.
II. Summary of Information From Postmarketing Study Progress Reports

This report summarizes the status of postmarketing commitments as of September 30, 2002. If a commitment did not have a schedule and a postmarketing progress report was not received, the commitment is categorized according to the most recent information available to the agency. Data in table 1 are numerical summaries generated from FDA databases. The data are broken out according to application type (NDAs/ANDAs or BLAs).

<table>
<thead>
<tr>
<th>Status of open postmarketing commitments</th>
<th>NDAs/ANDAs (% of total)</th>
<th>BLAs (% of total)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pending</td>
<td>820 (61%)</td>
<td>67 (30%)</td>
</tr>
<tr>
<td>Ongoing</td>
<td>285 (21%)</td>
<td>102 (46%)</td>
</tr>
<tr>
<td>Delayed</td>
<td>25 (2%)</td>
<td>17 (8%)</td>
</tr>
<tr>
<td>Terminated</td>
<td>8 (1%)</td>
<td>2 (1%)</td>
</tr>
<tr>
<td>Submitted</td>
<td>201 (15%)</td>
<td>35 (16%)</td>
</tr>
<tr>
<td>Concluded studies</td>
<td>349</td>
<td>52</td>
</tr>
<tr>
<td>Commitment met</td>
<td>240 (69%)</td>
<td>47 (90%)</td>
</tr>
<tr>
<td>Commitment not met</td>
<td>0 (0%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Study no longer needed or feasible</td>
<td>109 (31%)</td>
<td>4 (8%)</td>
</tr>
</tbody>
</table>

Open postmarketing commitments with annual report due but not received: 289 (22%) 77 (35%)